# Telemachus Therapeutics, Inc.: Form D capital raise (Wexford, PA)

**Vendor Spend Propensity Score (CPA / Tax / Audit):** 62/100
**Estimated post-raise budget for this service type:** $7,500 (heuristic)

| Field | Value |
|---|---|
| Industry | Pharmaceuticals (Healthcare & Life Sciences) |
| Operating company | Yes |
| Exemption | 506(b) |
| Amount sold | $375,000 |
| Total offering | $1,500,000 |
| Investors so far | 3 |
| First sale | 2026-08-20 |
| Filed | 2026-10-28 (amendment) |
| Entity | Corporation, incorporated 2026 |

## Executives and related persons (as listed in the filing)
- Michael Bozik: Executive Officer, Director, Promoter
- Gregory Hebrank: Executive Officer, Director, Promoter

## Why this score
- Operating company: new capital typically funds hiring, facilities and vendors.
- Raised $375,000 so far: a smaller raise.
- Healthcare & Life Sciences companies are a strong fit for CPA / Tax / Audit services.
- Filed 7 days ago.
- Incorporated in the last five years: likely still building out finance and insurance.

Source: SEC EDGAR Form D filings (U.S. Securities and Exchange Commission) (https://www.sec.gov/Archives/edgar/data/2152986/000215298626000002/). Last refreshed: 2026-11-04T09:16:10.755Z.
Informational only. SEC EDGAR Form D data is shown for business-development research; it is not investment advice and not an offer or solicitation to buy or sell any security. Not legal or financial advice.